The emergence of Retatrutide ZPHC, at a dosage of 120mg, is sparking considerable interest within the medical community. This groundbreaking dual GIP and GLP-1 target medication suggests to provide notable improvements in weight shedding compared to previous therapies. Preliminary research studies have demonstrated significant declines in body mass